![Revvity](https://healthindia.distilinfo.com/wp-content/uploads/sites/9/2023/11/0012.jpg)
Revvity’s T-SPOT.TB test unveiled at MICROCON in Lucknow revolutionizes latent tuberculosis (TB) screening in India. Leveraging ELISPOT technology, this FDA-approved test standardizes peripheral blood mononuclear cell isolation, ensuring consistent, reliable results—essential for complex-to-screen groups. Shripad Joshi, Revvity’s President, underscores the urgent need to detect latent TB among 40% of India’s population. Committing to collaboration with public and private healthcare sectors, Revvity aims to integrate this single-visit test into India’s healthcare infrastructure, enhancing accessibility and affordability. With 20 years of TB screening expertise, Revvity envisions reducing active TB cases, cutting costs, and saving lives through advanced screening tools.
Revvity, a pioneering Diagnostics, and Life Sciences company introduces its game-changing T-SPOT.TB test for latent TB screening in India. Unveiled at MICROCON in Lucknow, this FDA-approved assay, based on ELISPOT technology, promises standardized, precise results by isolating and quantifying peripheral blood mononuclear cells. Shripad Joshi, Revvity’s President, highlights the imperative nature of detecting latent TB among India’s 40% infected population. Their commitment to collaborating with Indian healthcare sectors aims to seamlessly integrate the T-SPOT.TB tests into the country’s healthcare system, enhancing accessibility and affordability. Revvity’s rich 20-year experience in TB screening fuels its mission to decrease active TB cases and costs while saving lives.
Revvity’s T-SPOT.TB Launch: Advancing Latent TB Screening in India
The T-SPOT.TB by Revvity stands as the sole FDA-approved IGRA (interferon-gamma release assay) available commercially, leveraging the ELISPOT technology. This innovative method involves the precise isolation, cleansing, and quantification of peripheral blood mononuclear cells (PBMCs) obtained from whole blood. Its methodology ensures standardized testing protocols, delivering consistent and trustworthy results, even among complex-to-screen populations, such as individuals with compromised immune systems.
Shripad Joshi, President for India & South Asia at Revvity, emphasized the pressing need to identify latent TB infections among the Indian populace. With an estimated 40% of the country’s population affected by latent TB, early detection plays a pivotal role in preventing the progression to active, symptomatic, and contagious TB. Joshi highlighted Revvity’s commitment to collaborating with both public and private healthcare sectors to integrate their single-visit T-SPOT.TB tests seamlessly into the existing healthcare infrastructure. This strategic approach aims to enhance the accessibility and affordability of latent TB screening across India.
Highlighting Revvity’s extensive experience spanning two decades in TB screening, Joshi underscored the company’s successful partnerships with multiple healthcare systems worldwide. Expressing enthusiasm about introducing advanced screening tools to healthcare professionals in India, he stressed the significance of supporting the government’s mission to eradicate TB by 2025. Joshi pointed out that employing such innovative tools not only aids in effective disease detection but also reduces the economic burden associated with treating active or drug-resistant TB cases, ultimately contributing to saving lives.
Revvity’s introduction of the T-SPOT.TB test in India marks a pivotal moment in combatting TB, promising enhanced efficiency, accuracy, and accessibility in latent TB screening, aligning with the nation’s healthcare objectives and the global fight against tuberculosis.
Revvity’s launch of the T-SPOT.TB test marks a transformative milestone in latent TB screening in India. This groundbreaking assay, unveiled at MICROCON in Lucknow, brings standardized, reliable results to complex-to-screen populations, addressing the urgent need to detect latent TB among 40% of India’s populace. Shripad Joshi, Revvity’s President, emphasizes collaboration with public and private healthcare sectors to seamlessly integrate the test into India’s healthcare infrastructure. With two decades of TB screening expertise, Revvity anticipates reducing active TB cases, cutting treatment costs, and ultimately, preserving lives through the deployment of advanced screening tools in India’s healthcare landscape.